Hopp til innhold

Get alerts of updates about «Health technology assessment of 177Lu- PSMA-617 treatment for metastatic castration resistant prostate cancer - Protocol for Health technology assessment»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Health technology assessment of 177Lu- PSMA-617 treatment for metastatic castration resistant prostate cancer - Protocol for Health technology assessment

Project

Health technology assessment of 177Lu- PSMA-617 treatment for metastatic castration resistant prostate cancer - Protocol for Health technology assessment - project description

Published Updated


Summary

Prostate cancer is the most common cancer type among Norwegian men. In 10-20% of these patients, the cancer will advance to metastatic, castration resistant prostate cancer (mCRPC). As mCRPC is incurable, the treatment options are limited to palliative therapy, using radiation and chemotherapy to manage symptoms and prolong life. Radioligand therapy (RLT) is increasingly being used for treating various malignancies. RLT of mCRPC uses the radionuclide lutetium-177 coupled with a binding ligand for prostate-specific membrane antigen (PSMA).

The Norwegian Institute of Public Health has been commissioned to assess the efficacy and safety of 177Lu-PSMA-617 treatment of prostate cancer, in addition to organisational scenarios and health economic consequences with this treatment, in a full health technology assessment (HTA).We will perform a systematic search for literature in relevant databases. References will be screened for title, abstract and full-text, and included in accordance with predetermined selection criteria. We will extract and analyse data from the included studies, and the results will be compiled and presented in a report written in English. The methodological quality of the included studies will be assessed, as will the certainty of the evidence, i.e., our confidence in the results. We will also perform a health economic evaluation and a five-year budget impact. If we receive a documentation package from Novartis, we will implement this in our work, while still maintaining to perform a full HTA.

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Ingrid Kristine Ohm, Norwegian Institute of Public Health

Project participants

Martin Robert Lerner, Norwegian Institute of Public Health
Anna Karina Stoinska-Schneider, Norwegian Institute of Public Health
Gunn Eva Næss, Norwegian Institute of Public Health
Ingeborg Beate Lidal, Norwegian Institute of Public Health
Beate Charlotte Fagerlund Kvist, Norwegian Institute of Public Health

Start

15.06.2022

End

15.06.2023

Status

Active

Project owner/ Project manager

Norwegian Institute of Public Health